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Abstract
Non-muscle invasive bladder cancer (NMIBC) is the more common type of bladder cancer 
(75%). However, within this group of cancer, there is a spectrum of disease, with low grade, 
low risk tumours which rarely recur or progress at one end of the spectrum, to high grade, 
high risk tumours that have a significant risk of recurrence and progression to muscle 
invasive bladder cancer (MIBC).
Management involves risk-adapted strategies of Cystoscopy based surgery, including 
TURBT (Transurethral Resection of Bladder Tumour), Cystoscopy surveillance, including 
Check Flexible Cystoscopy (performed under local anaesthesia), and intra-vesical Chemo / 
Immunotherapy with the goal of preserving the bladder when it is safe to do so.
Rarely, high risk NMIBC may require more radical treatment including radical cystectomy 
and appropriate urinary diversion. However, the local recurrence and long-term survival rates 
are much better when compared to radical treatment for MIBC.
Introduction
Bladder cancer (BC) is the most common malignancy of the urinary tract1. It is the 11th most 
commonly diagnosed cancer in the world2. In the UK, it is the seventh most common cancer. 
The Worldwide age standardised incidence rate (per 100,000 person-years) is 8.9 for men and 
2.2 for women (2008 data)2.  Worldwide, BC is the 14th leading cause of cancer deaths, age-
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standardised mortality rate (per 100.000 person-years) was 3.3 for men versus 0.9 for women 
in 2008. BC causes 5,369 deaths per year in the UK and has a survival rate of 50% at 10 
years3. BC incidence and mortality rates vary across different countries due to differences in 
risk factors, detection and diagnostic practices, and availability of treatments4. Smoking is the 
most established risk factor for BC, while other risk factors include occupational exposure to 
aromatic amines and hydrocarbons. Approximately 75% of patients with BC present with a 
disease confined to the mucosa (stage Ta, CIS) or submucosa (stage T1) and are classified as 
Non-muscle invasive bladder cancer (NMIBC). They have a high prevalence due to long-
term survival in many cases and lower risk of cancer specific mortality compared to T2-4 
tumours, which are classified as Muscle invasive bladder cancer (MIBC)1, 5.
Pathophysiology and Types
The bladder is lined with transitional epithelium which is composed of layers of epithelia 
allowing the bladder to expand as it fills with urine. Most cancers of the bladder are 
epithelial-derived2. Pathological subtypes of epithelial bladder cancers include:
• Transitional Cell Carcinoma-this is the most common epithelial subtype (>90%) 
• Squamous Cell Carcinoma (5%)
• Adenocarcinoma (<2%)
Non-epithelial-derived cancers such as lymphomas and sarcomas also make up a small 
proportion of cancers. 
Risk Factors
The incidence of bladder tumours increases with age, with the majority of cases being 
diagnosed in those over the age of 50. There are number of modifiable risk factors which 
should be identified in the patients social, occupational and travel history6. In western 
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countries, smoking is the single biggest modifiable risk factor for developing bladder cancer 
with smokers having a 2-6 times greater risk7. One meta-analysis of epidemiological studies 
demonstrated that 50% of male and 34.8% of female patients who developed bladder cancer 
had a smoking history8.  The risk increases with the number of pack years smoked; and 
although quitting smoking reduces the ongoing risk of developing bladder cancer, cessation 
does not reduce risk to the level of lifelong non-smokers9. 
Occupational exposure to carcinogenic chemicals such as aromatic amines, polycyclic 
aromatic hydrocarbons and chlorinated hydrocarbons found in paint, rubber and dye 
manufacturing have been proven to have a contributing factor in 10% of cases10. Chronic 
irritation of the bladder leads to an increased risk of developing squamous cell carcinoma; 
this can be due to long-term catheterization or bladder stones. In regions of the world with 
endemic levels of Schistosomiasis, chronic infection from this parasite leads to chronic 
cystitis11.  Squamous Cell Carcinoma accounts for 75% of bladder cancers in these regions12. 
Clinical Presentation
Patients with NMIBC commonly present with gross, painless, visible haematuria (VH)6. They 
may also present as non-visible haematuria (NVH), usually picked up on routine urinalysis 
using dipstix examination (Figure 3). Patients may also complain of Lower Urinary Tract 
Symptoms (LUTS) of storage, including frequency and urgency and sometimes dysuria, 
especially in the presence of carcinoma in situ (CIS) of the bladder.  It is important to note 
that storage LUTS may also be the presenting symptoms in patients with urinary tract 
infections (UTIs). However, it is useful to remember that the diagnosis of UTI does not 
automatically exclude a bladder cancer, as both could be present in the same patient. 
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Figure 1 – TNM staging of Bladder Cancer – also demonstrating the different layers of 
bladder histology and their relation to bladder cancer staging
Heamaturia Clinic and Investigations
Patients with both VH and NVH are referred by the GPs via the 2 week wait pathway to the 
Rapid Access Haematuria clinic. This is provided in the form of a “One-Stop” service during 
which clinicians take a detailed history, perform thorough clinical examination and carry out 
investigations, (summarized in figure 2). This allows the patient to be informed of their 
diagnosis on the same day of their initial out-patient appointment and reduces the anxiety and 
delay for both, the patients and clinicians who are planning their management. 
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In addition to the information given in Figure 2, a detailed history taking regarding VH 
should also include the timing of its occurrence in relation to the urinary stream, which may 
give clues to the possible site of the underlying pathology. Initial haematuria refers to patient 
seeing blood at the beginning of micturition. This may suggest a possible urethral pathology. 
Mixed haematuria implies the presence of blood mixed throughout the urinary stream, which 
may indicate that the pathology is possibly in the upper urinary tract (kidneys, ureters) or 
bladder. Terminal haematuria is seen at the end of voiding urine suggesting that the 
underlying pathology is possibly in the bladder neck or prostate.
 Clinical examination of the patient may reveal useful information including other pathology. 
Supra-pubic tenderness may suggest cystitis related to UTI. A palpable bladder may be 
found, if the patient is in retention of urine. Renal angle fullness may suggest hydronephrosis 
or a renal mass, which will be typically bi-manually palpable and / or ballotable. Just 
tenderness in the renal angle may suggest pyelonephritis. Genital examination may reveal 
phimosis and / or meatal stenosis. Digital Rectal Examination (DRE) is an integral part of the 
abdominal examination and may reveal nodule(s) or hardness in the prostate suggestive of 
malignancy or a smooth, firm enlargement of the prostate suggestive of BPE (Benign 
Prostatic Enlargement), which is the most common cause of visible haematuria in a man. 
Tenderness in the prostate may suggest prostatitis.
 The mainstay of investigations is imagining and endoscopy. Flexible cystoscopy (Figure 4) 
allows direct visualization of bladder tumours.  Small tumours and suspicious areas in the 
bladder mucosa may be biopsied and biopsy sites diathermied, under flexible cystoscopy 
guidance.
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 Figure 3- The progress of patient through the rapid access haematuria clinic
Figure 2- The progress of patient through the rapid access haematuria clinic
HISTORY TAKING
• Visible haematuria (onset, duration, painful / painless, volume, any clots?)
• Non-visible haematuria (diagnosis setting e.g. Routine medical at work)
• LUTS (frequency, urgency, dysuria, voiding difficulty - clot retention of urine)
• Systemic symptoms (tiredness, weakness, loss of appetite / weight, bone pain)
• Risk factors (smoking, occupation – mechanics, factory / industry workers, hair dressers)
• Current medications (anticoagulants)
EXAMINATION
• General examination (anaemia, dehydration, heart rate, BP)
• Systematic examination (abdomen, external genitalia, rectal / vaginal examination)
INVESTIGATIONS
• Urinalysis - Dipstix testing (blood, protein, leucocytes, nitrites, pH) 
• MSSU (Mid-stream specimen of urine) – M, C&S (microscopy, culture & sensitivity)
• Blood tests (FBC, U&Es, PSA in men)
• Urine Cytology (usually not required during initial investigation)
• US-KUB  – for patients < 50 years of age with NVH 
• CTU – in all patients with VH and in patients > 50 years of age with NVH
• Flexible Cystoscopy – in all patients with VH and patients > 50 years of age with NVH
• Urinary Biomarkers – BTA (Bladder Tumour Antigen); NMP-22 (Nuclear Matrix 
Protein); UroVysion (FISH assay – Fluorescent in situ Hybridization assay)
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Figure 3 – Urine Dipstix for testing – reagents change colour with positive tests
Figure 4 – Flexible Cystoscope – commonly used in out-patient setting
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Figure 5 - Different appearances of Non-muscle invasive bladder cancer at Cystoscopy
                                         Figure 6 – CT-IVU appearance of a bladder cancer
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Urine Cytology
Urine cytology forms part of routine initial evaluation of VH and NVH in some centres. 
However, in many centres, including ours, it is reserved as a second line investigation, if the 
initial investigations fail to demonstrate a cause for haematuria. The criticism about urine 
cytology is due its low sensitivity to detect low risk NMIBC, especially. It has a relatively 
higher sensitivity for high risk NMIBC. However, the specificity to detect NMIBC is much 
higher for urine cytology i.e. there is not many false positive results. So, if a patient has 
positive urine cytology, it is almost certain that there is Urothelial Carcinoma (UC) 
somewhere within the urinary tract, not necessarily bladder or urethra but may be in the 
ureters or kidneys. Thus, urine cytology can be judiciously used in the diagnosis and / or 
follow-up of patients with high risk NMIBC. 
The Urinary Biomarkers, BTA, NMP-22 and UroVysion may be used instead of or along 
with urine cytology to aid the diagnosis of NMIBC13. 
Initial Management 
(TURBT + Intra-vesical Mitomycin C)
In the event a suspicious lesion identified during cystoscopy, the patient would need to be 
urgently scheduled to have a Trans-Urethral Resection of Bladder Tumour (TURBT). This 
procedure is both therapeutic and diagnostic. It is the best way to get the lesion pathologically 
assessed to confirm the extent of disease. The detrusor muscle should ideally be included in 
the specimen sent for Histopathological examination, especially, to ensure that the cancer 
isn’t muscle invasive. Absence of detrusor muscle in a biopsy has been linked to a greater 
risk of the patient having residual disease14.
The European Association of Urology (EUA) guidelines states that a bimanual examination 
should be carried out after a TURBT to assess for the presence of residual masses or 
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thickening of the bladder which may indicate muscle invasive disease, while immobility of 
the bladder and pelvic organs may suggest T4 disease14. Immediately after the TURBT a 
single dose of intra-vesical chemotherapy is ideally given to the patient. The chemotherapy 
drug commonly used is Mitomycin C (MM-C). Mitomycin C is a drug which is isolated from 
the culture of Streptomyces caespitosus6. It’s mechanism of action is alkylation and cross-
linking of DNA strands which results in cancer cell death. MM-C is a large molecule and this 
prevents its systemic uptake thus limiting its effects to the local area of administration. The 
general complications that can arise from intra-vesical chemotherapy are LUTS of storage, 
skin desquamation and skin rash in the short term, but in the long term patients could 
potentially end up with bladder fibrosis and contracture6, 14.
Staging
Bladder cancer is staged (Figure 1) using the Tumour, Node, Metastases system (2002). 
Union International Centre le Cancer, updated it in 200914, 15. Non-muscle invasive cancer 
(NMIBC), sometimes referred to as “Superficial bladder cancer” are tumours of stages: Ta, 
T1 and Tis which are confined to the bladder mucosa, including the lamina propria (T1) 
(Table 1, Figures 1). Tumours which invade the bladder muscle, and deeper are staged T2 
and greater (Figure 1).
T – Primary Tumour
Ta Papillary Tumours confined to Epithelial Mucosa
T1 Tumours Invading Sub epithelial Tissue (i.e. lamina propria)
Tis Carcinoma in situ – flat high-grade tumours confined to the mucosa appear as 
inflammatory lesions.
Table 1- TNM staging of Non-muscle Invasive Bladder Cancer
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Papillary non-muscle invasive bladder tumours are graded based on the degree of 
differentiation. The older WHO classification (1973) used a numerical system for grading 
tumours:
• Urothelial papilloma
• Grade 1: well differentiated (G1)
• Grade 2: moderate differentiated (G2)
• Grade 3: poorly differentiated (G3)
More recently the World Health Organization (WHO) in 2004 reclassified these tumours as 
below:
• Urothelial papilloma (completely benign lesion)
• Papillary urothelial neoplasm of low malignant potential (PUNLMP)
• Low-grade (LG) papillary urothelial carcinoma
• High-grade (HG) papillary urothelial carcinoma
This older grading system is still frequently seen in clinical practice and some units use both 
systems in parallel. The two systems are not equivalent with Grade 1 tumours becoming 
Papillary urothelial neoplasm of low malignant potential (PUNLMP) or Low-grade (LG) 
papillary urothelial carcinoma, Grade 2 tumours assigned to Low-Grade or High-Grade and 
all previous Grade 3 tumours are now High-Grade (Table 2).
Table 2 - Comparison of WHO grading 1973 and 2004 10, 11
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Carcinoma in Situ is subdivided into three clinical types:
• Primary: isolated CIS with no previous or concurrent papillary tumours and no 
previous CIS
• Secondary: CIS detected during follow-up of patients with a previous tumour that was 
not CIS
• Concurrent: CIS in the presence of any other urothelial tumour in the bladder
Follow up & Further Management
Bladder cancer has a high recurrence rate (50–70%) therefore it is important to follow up 
patients regularly to identify patients who would require further therapy6. This surveillance 
mainly involves a repeat cystoscopy every 3-6 months depending on risk stratification. 
Patients are divided into either the low, intermediate and high risk groups. Divisions are made 
using the pathological report of the specimens collected during TURBT and the number and 
size of tumours visualized14. This division is used to aid disease management (Table 3) and 
determine length of follow-up.
The follow-up regime mentioned in Table 3 is based on the National Institute for Clinical 
Excellence (NICE) guidelines16 for NMIBC (2015). Some Urologists are however 
uncomfortable to discharge patients in the low risk group after only 12 months follow-up. 
They prefer to continue cystoscopy surveillance on an annual basis for up to 5 years as was 
hitherto practiced in the UK. 
13
Risk Group Histology Follow Up
Low solitary pTaG1/ pTaG2 (low grade) -
diameter of less than 3 cm
Papillary urothelial neoplasm of low 
malignant potential
Cystoscopy surveillance for 12 months
Intermediate solitary pTaG1/ pTaG2 (low grade) - 
diameter of more than 3 cm
multifocal pTaG1/ pTaG2 (low grade)
pTaG2 (high grade)
low-risk non-muscle-invasive bladder 
cancer recurring within 12 months
of last tumour occurrence
Intravesical MMC - weekly x 6 




aggressive variants e.g. micro papillary 
or
nested variants
2nd TURBT  to exclude muscle invasive 
disease 
Either: 
Intravescial maintenance BCG then 
Cystoscopy surveillance for 10 years
or Radical Cystectomy 
 P = Pathological - this information is obtained from histology rather than clinical examination or imaging
Table 3 -Management and Follow up Plan for NMIBC16
The follow-up of NMIBC involves cystoscopy surveillance for a period of 5-10 years but 
patients with intermediate and high risk disease also receive adjuvant intra-vesical treatment 
once muscle invasive disease has been excluded. This can be in the form of chemotherapy 
(MM-C), as mentioned earlier in this article or in the form of immunomodulators. The most 
commonly used immunomodulator is BCG - Bacillus Calmette-Guérin17. BCG is a vaccine 
that was initially developed to prevent tuberculosis but has been found to be useful in the 
treatment of bladder cancer. It’s mechanism of action in the bladder is not completely 
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understood. However, it is thought that the vaccine stimulates a local immune response 6 
against the tumour cells via the promotion of pro-inflammatory cytokines (e.g. IL-1, IL-6, IL-
8 and TNF - tumour necrosis factor). Complications related to BCG use include, cystitis, 
granulomatous prostatitis, disseminated tuberculosis, BCG sepsis and death. BCG induction 
consists of 6 doses given weekly. Studies have shown that giving further maintenance BCG 
for up to 3 years improves the response18.
NICE recommends that patients with High Risk NMIBC should be offered the choice of 
primary cystectomy or BCG and the benefits and risks of both options discussed16.  For 
patients who are refractory to BCG or not-tolerant, radical cystectomy is the treatment of 
choice. However those patients who are unfit or have decided against radical cystectomy may 
be offered alternative options depending on local policies. These can include further BCG 
induction therapy or device assisted intravesical chemotherapy in the form hyperthermia 
MMC or electromotive drug administration of MMC.
If cystectomy is performed, urinary diversion is done either through an ileal conduit (non-
continent diversion) or the formation of a neobladder or abdominal pouch (continent 
diversion). Both forms of diversions require the use of a section of bowel which could lead to 
complications such as electrolyte disturbances, sepsis, and malabsorption of vitamins, bowel 
obstruction and the formation of renal calculi.
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Recurrence & Progression
Recurrence involves the formation of a new lesion of the same histological grade, whereas 
progression means that the tumour has advanced in its pathological stage. Various factors are 
used when determining prognosis and the risk of recurrence or progression (Figure 5). The 
most important of these are histology and grade of the tumour. Carcinoma-in-situ is 
associated with a greater chance of progression to invasive disease.
Figure 7 - Factors used to assess prognosis 19, 20
Risk progression scores have been developed in order to predict disease recurrence and 
progression however; these do not include patients with the presence of CIS alone16. CIS is 
only included in patients with concurrent papillary disease. Recurrence and progression 
scores are given with regards to tumour grade/number, size, previous recurrence and presence 






2-7 3 3Number  of 
Tumours
>7 6 3
Tumour diameter >3 cm 3 3
< 1 recurrence/year 2 2Prior recurrence 
rate
> 1 recurrence/year 4 2
Category T1 1 4
Concurrent CIS Yes 1 6
G2 1 0Grade
G3 2 5








Progression at 5 years
0 15% 0 0.2%
1-4 24% 2-6 1%
5-9 38% 7-13 5%
10-17 61% 14-23 17%
Table 4, 5 - Probability of recurrence and progression20
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Conclusion
NMIBC should be considered in patients presenting with VH and / or NVH. Those at risk 
should be investigated quickly at the two week wait haematuria rapid-access clinic. Late 
detection and management could potentially lead to muscle-invasive disease with greater 
morbidity and mortality. Therefore it is imperative for patients to undergo imaging and 
cystoscopy as quickly as possible for a definitive diagnosis and to plan definitive treatment 
such as TURBT.  Patients are risk stratified based on their histopathology results. Further 
management including appropriate intra-vesical adjuvant MMC or BCG treatment and 
cystoscopy surveillance is based on the risk group that the patient belongs to. The aim of the 
treatment for NMIBC in general, is to preserve the bladder. However, some patients who 
have high risk or progressive disease may opt for or need radical cystectomy followed by an 
appropriate form of urinary diversion. 
Multiple Choice Questions
1. A 67 year old British man presents with frank painless haematuria. Which of the 
follow risk factors is most important to establish whilst taking the history?
a) History of recurrent UTIs
b) Smoking
c) Hyperparathyroidism
d) Occupational exposure to aromatic amines
e) Schistosomiasis
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2. The patient’s GP decides to refer him for further investigation. What is the gold 




d) Renal Function Tests
e) Cystoscopy
3. A 71 year old male patient is referred to Urology. Investigation demonstrates a 
papillary lesion visualized within the bladder. A biopsy is taken which is sent for 
histology. This shows that the tumour invades the lamina propria but does not invade 








4. A 65 year old female patient undergoes TURBT and is given the diagnosis of a 
pTaG2 (high grade) bladder tumour. She is given an intravesical dose of Mitomycin 
C. Which of the following is the most appropriate regime of surveillance for 
reoccurrence?
a) No follow-up required
b) Cystoscopy surveillance for 12 months
c) Further maintenance MMC and Cystoscopy surveillance for 12 months
d) Further maintenance MMC and Cystoscopy surveillance for 5 years 
e)  2nd TURBT, Intravescial BCG and Cystoscopy surveillance for 10 years
5. A 60 year old patient with high risk disease undergoes a second TURBT which shows 
disease progression. The histology report grades the lesions as muscle invasive. What 
would be the most appropriate management option for this patient?
a) No further management required
b) Repeat cystoscopy in 3 months
c) Verify eligibility for radical cystectomy.





D is also important to ask about however it is not the most important risk factor 
associated with Non muscle invasive bladder cancer. E is relevant in patients who have 
migrated or travelled to countries where schistomiasis is prevalent.
2. Answer E
Cystoscopy allows direct visualization of the tumour and is also the only way to diagnose 
CIS.
3. Answer C
T1 disease is defined as tumours invading sub epithelial tissue but that does not invade 
the superficial muscle layer.
4. Answer D
The patient’s disease would fall into the intermediate risk group. A is incorrect as every 
risk group is followed up, B is for the low Risk group, D is for the intermediate risk 
group, E is for the high risk group and C doesn’t fit any of the risk groups
5. Answer C
A and B are incorrect given the progression of high grade disease. E is incorrect as the 
question stem hasn’t indicated that the patient is at the stage of palliative therapy yet. 
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